PBMCs isolated from T2DM patients displayed a higher leptin secretion in response to IL-2 and HMGB1 co-treatment vs. IL-2 (p < 0.005) and HMGB1 (p < 0.05) single treatments (Figure 8). The gene discussed is IL2; the disease is type 2 diabetes mellitus.